ArticleKidney & blood pressure research2026
Nobiletin from Xiaoyu Xiezhuo Decoction: Restoring Mitochondrial Dynamics and Alleviating Renal Ischemia-Reperfusion Injury via M1 Macrophage Modulation.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere have been reports that the traditional Chinese medicine formula Xiaoyu Xiezhuo Decoction (XYXZD) protects against kidney injury. Its possible mechanisms in renal ischemia-reperfusion injury (IRI) remain unclear, though. Investigating XYXZD's function and possible therapeutic effects on renal IRI is the goal of this investigation.
methodsLiquid chromatography-mass spectrometry and network pharmacology were applied to identify key target genes associated with XYXZD and renal IRI. Molecular docking was employed to forecast the binding affinity of bioactive compounds to these targets. The effects of nobiletin (NOB) on macrophage polarization, inflammatory cytokine production, mitochondrial function, and oxidative stress were evaluated. The impact of NOB on HK-2 mitochondrial dynamics through M1 macrophage polarization was evaluated via the cell counting kit-8 assay, enzyme-linked immunosorbent assay, Western blotting, and transmission electron microscopy.
resultsNetwork pharmacology analysis identified matrix metalloproteinase-9 (MMP9) and poly(ADP-ribose) polymerase 1 (PARP1) as key regulatory factors linking macrophage polarization and mitochondrial function. Molecular docking revealed a strong binding affinity between NOB and MMP9. NOB reduced M1 macrophage polarization, along with the downregulation of pro-inflammatory cytokines interleukin-1 beta and interleukin-6. In HK-2 cells, NOB mitigated mitochondrial dysfunction by modulating M1 macrophage polarization, reducing reactive oxygen species production, and restoring mitochondrial dynamics.
conclusionBy preventing M1 macrophage polarization, lowering inflammation, and reestablishing mitochondrial homeostasis in renal tubular epithelial cells, this study showed that NOB has renoprotective benefits. These results provided fresh perspectives on NOB's potential as a treatment for renal IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.